Cimpress to Present at the 19th Annual Needham Technology, Media, & Consumer Conference on May 15th in New York, NY
Cimpress plc (Nasdaq: CMPR) today announced that Meredith Burns, Vice President of Investor Relations and Sustainability, will present at the Needham Technology, Media, & Consumer Conference on Wednesday, May 15, 2024, in New York, NY. Cimpress plc's presentation is scheduled to begin at 8:45am ET.
The presentation will be webcast and can be accessed through the Cimpress Investor Relations website at ir.cimpress.com/news-and-events/events, and a replay of the presentation will be available at the same link for 90 days following the event.
About Cimpress
Cimpress plc (Nasdaq: CMPR) invests in and builds customer-focused, entrepreneurial, print mass-customization businesses for the long term. Mass customization is a competitive strategy which seeks to produce goods and services to meet individual customer needs with near mass production efficiency. Cimpress businesses include BuildASign, Drukwerkdeal, Exaprint, National Pen, Pixartprinting, Printi, Vista, and WIRmachenDRUCK. To learn more, visit cimpress.com.
Cimpress and the Cimpress logo are trademarks of Cimpress plc or its subsidiaries. All other brand and product names appearing on this announcement may be trademarks or registered trademarks of their respective holders.
eWTP Arabia Capital Technology Fund I ("Techology Fund I"), managed by eWTP Arabia Capital ("eWTPA"), one of the leading private equity firms in the Middle East, was listed in the Preqin League Tables as the the fifth top-performing VC funds in the...
Celltrion partners with TV star Mollie Pearce to launch the second installation of the Where's Crohn's & Colitis (CC)? campaign for this year's World IBD Day (19 May 2024).
The campaign focuses on access to IBD care and treatment as the burden of...
The global industrial automation market in life sciences industry size is estimated to grow by USD 5.06 bn from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of 11.4% during the forecast period. ...
Gilead Sciences, Inc. , following the recent acquisition of CymaBay Therapeutics, Inc., today announced interim results from the ongoing ASSURE study demonstrating treatment with seladelpar, an investigational PPAR delta agonist, led to improvements...
Mirum Pharmaceuticals, Inc. today announced data presented during the 56th European Society for Paediatric, Gastroenterology, Hepatology, and Nutrition (ESPGHAN) Annual Meeting which took place this week in Milan, Italy. Data from LIVMARLI®...